Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank

1 year ago

SAN DIEGO and TORONTO, March 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO; TSX:…

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within Three Prominent Colorado Pain Management Clinics

1 year ago

Follows successful evaluation by Dr. Brad Sisson, MD, including complex thoracic proceduresROSELAND, N.J., March 10, 2023 (GLOBE NEWSWIRE) -- Milestone…

Novelion Announces Completion of Plan of Liquidation and Distribution and its Voluntary Dissolution

1 year ago

VANCOUVER, British Columbia, March 10, 2023 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal…

ProSomnus® Announces Acceptance of Abstract at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference

1 year ago

PLEASANTON, Calif., March 10, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices…

Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

1 year ago

FORT LEE, NJ, March 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the…

Ascendis Pharma to Participate in the Oppenheimer 33rd Annual Healthcare Conference

1 year ago

COPENHAGEN, Denmark, March 10, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President &…

PetVivo Holdings, Inc. to Exhibit and Dr. Erik Kleeman of Ethos Veterinary Health to Present Canine Study Results at the Veterinary Orthopedic Society Annual Conference

1 year ago

MINNEAPOLIS, MN, US, March 10, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo")…

89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

1 year ago

– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 – – Feedback from FDA…

Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

1 year ago

-- Full results from ELPIS I trial published in European Heart Journal Open –         -- First patient to be randomized…

Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology

1 year ago

MALVERN, Pa., March 10, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing…